Jing Liu

TL;DR: The main contents include epidemiology of type 2 diabetes in China; diagnosis and classification of diabetes; primary, secondary, and tertiary diabetes prevention; diabetes education and management support; blood glucose monitoring; integrated control targets for type 1 diabetes and treatments for hyperglycaemia.

TL;DR: Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China Department of Endocrineology, Peking University People’s Hospital, Beijing, China Shanghai Diabetes Institute, Shanghai Clinical Center for Diabetes, Shanghai Key laboratory of Diabetes Mellitus.

TL;DR: Evidence is provided that acarbose is similar to metformin in efficacy, and is therefore a viable choice for initial therapy in Chinese patients newly diagnosed with type 2 diabetes.

TL;DR: Glycemic control decreased and insulin use increased with the duration of diabetes, and the efficacy of oral antidiabetes drugs, glucagon-like peptide-1 (GLP-1) receptor agonists and insulin for treatment of T2DM across multiple regions in China was assessed.

TL;DR: Age, sex, body mass index, snoring, reported breath‐holding in sleep or gasping or choking arousal, sleepiness, diabetes duration, hypertension, diabetic nephropathy and cardiovascular diseases history were correlated significantly with the severity of obstructive sleep apnea.